Survey on satisfaction of external quality assessment among tuberculosis laboratory network in China

doi:10.19982/j.issn.1000-6621.20230013

Abstract

Abstract:

Objective: To identify the problems in the external quality assessment (EQA) of tuberculosis laboratories diagnosis and improve the quality through a satisfaction survey among tuberculosis laboratories network in China. Methods: The National Tuberculosis Reference Laboratory (NTRL) of Chinese Centre for Disease Control and Prevention designed and distributed online questionnaires to personnel involved in EQA in 2019, 2020 and 2021. The questionnaires were anonymously filled by personnel and then collected and analyzed by NTRL. The difference of satisfaction between 2019 and 2021 was analyzed, and the difference between personnel form different levels of institutes (provincial, prefecture, and county) in 2019 was also compared. Results: One thousand six hundred and fifteen, 30 and 314 personnel responded to the questionnaire in 2019, 2020 and 2021 respectively. Of the 25 questions in 2021, only psychological stress satisfaction (79.0%, 248/314) was less than 80%. Of the 26 questions in 2019, the satisfaction rate of four questions was below 80%, such as satisfaction of the impact on work load (69.3%, 1120/1615), satisfaction of the impact on economic burden (76.3%,1232/1615), satisfaction with psychological stress (66.1%, 1067/1615), and satisfaction of application for strains transportation permission (75.4%, 724/960). Among the 24 common questions in 2019 and 2021, the satisfaction rate of 22 questions in 2021 (79.0%-97.4%) was significantly higher than that in 2019 (66.1%-97.0%) except for the two questions related to results reporting time requirement that had no significant difference between 2019 and 2021. Conclusion: The satisfaction of respondents with most questions relevant with EQA is acceptable. Satisfactions with most questions has been improved after implementing of improvement measures. Some aspects, such as results reporting form and strain transportation still need further improvement, however.

Key words: Tuberculosis, Laboratories, Health care quality, access, and evaluation, Consumer satisfaction, Questionnaires

CLC Number:

R521
R446

Song Yuanyuan, Xia Hui. Survey on satisfaction of external quality assessment among tuberculosis laboratory network in China[J]. Chinese Journal of Antituberculosis, 2023, 45(6): 559-565. doi: 10.19982/j.issn.1000-6621.20230013

Figures/Tables 2

问题	2021年	2019年	χ²值	P值	2019年
问题	2021年	2019年	χ²值	P值	省级	地市级	县(区)级	χ²值	P值
组织实施
总体时间安排
药敏试验	90.2 (222/246)	80.1 (745/930)	13.678	<0.001	85.0 (85/100)	81.0 (371/458)	77.7 (289/372)	3.100	0.212
分子检测	92.6 (286/309)	85.5 (1164/1361)	10.885	0.001	91.1 (92/101)	85.1 (371/436)	85.1 (701/824)	2.728	0.256
通知及方案描述易理解程度
药敏试验	93.4 (228/244)	82.9 (759/916)	17.004	<0.001	97.0 (96/99)	88.4 (402/455)	72.1 (261/362)	53.054	<0.001
分子检测	93.5 (289/309)	84.8 (1146/1352)	16.435	<0.001	97.0 (98/101)	85.0 (368/433)	83.1 (680/818)	13.474	0.001
与国家级/省级沟通时,反馈及时度及解决问题满意度
药敏试验	96.4 (242/251)	86.7 (862/994)	18.752	<0.001	96.9 (94/97)	90.0 (413/459)	81.1 (355/438)	25.199	<0.001
分子检测	95.6 (285/298)	89.2 (1186/1330)	11.676	<0.001	97.0 (97/100)	89.7 (392/437)	87.9 (697/793)	7.816	0.020
样本
样本状态及质量
药敏试验	95.9 (235/245)	83.0 (689/830)	26.098	<0.001	100.0 (98/98)	82.5 (367/445)	81.5 (234/287)	20.941	<0.001
分子检测	97.1 (300/309)	87.8 (1152/1312)	23.076	<0.001	95.0 (96/101)	88.4 (380/430)	86.6 (676/781)	6.218	0.045
样本数量
药敏试验	-	92.7 (696/751)	-	-	93.8 (90/96)	90.1 (392/435)	97.3 (214/220)	11.216	0.004
分子检测	-	97.0 (1242/1280)	-	-	99.0 (99/100)	96.4 (407/422)	97.1 (736/758)	1.860	0.395
结果报告
结果报告形式
药敏试验	93.0 (227/244)	85.6 (684/799)	9.324	0.002	93.8 (91/97)	86.4 (386/447)	81.2 (207/255)	9.568	0.008
分子检测	90.9 (280/308)	85.0 (1067/1255)	7.202	0.007	93.1 (94/101)	85.3 (367/430)	83.7 (606/724)	6.163	0.046
您对测试结果反馈通报及证书颁发时间满意度
药敏试验	91.4 (222/243)	82.7 (666/805)	10.734	0.001	86.6 (84/97)	82.1 (367/447)	82.4 (215/261)	1.162	0.559
分子检测	91.6 (283/309)	84.3 (1064/1262)	10.746	0.001	88.1 (89/101)	82.6 (357/432)	84.8 (618/729)	2.138	0.343
结果报告时间要求
药敏试验	96.6 (229/237)	93.6 (699/747)	3.119	0.077	94.8 (92/97)	94.1 (416/442)	91.8 (191/208)	1.534	0.464
分子检测	97.4 (297/305)	95.3 (1142/1198)	2.510	0.113	99.0 (100/101)	95.0 (403/424)	94.9 (639/673)	3.366	0.186
室间质量评价工作总体评价
工作负担	83.4 (262/314)	69.3 (1120/1615)	25.689	<0.001	79.8 (83/104)	65.6 (340/518)	70.2 (697/993)	9.041	0.011
经济负担	83.4 (262/314)	76.3 (1232/1615)	7.705	0.006	87.5 (91/104)	73.7 (382/518)	76.4 (759/993)	76.190	<0.001
精神压力	79.0 (248/314)	66.1 (1067/1615)	20.201	<0.001	78.8 (82/104)	61.2 (317/518)	67.3 (668/993)	13.698	0.001
真实反映工作能力	96.5 (303/314)	92.0 (1486/1615)	7.854	0.005	92.3 (96/104)	93.2 (483/518)	91.3 (907/993)	1.692	0.429
真实反映日常工作情况	95.9 (301/314)	91.0 (1469/1615)	8.346	0.004	92.3 (96/104)	90.9 (471/518)	90.8 (902/993)	0.249	0.883
对日常工作质量提升程度	96.8 (304/314)	93.7 (1514/1615)	4.566	0.033	95.2 (99/104)	93.6 (485/518)	93.7 (930/993)	0.397	0.820
工作成就感	97.1 (305/314)	91.5 (1477/1615)	12.042	<0.001	94.2 (98/104)	90.5 (469/518)	91.6 (910/993)	1.624	0.444
其他
表型药敏试验考核药物种类	89.3 (191/214)	80.7 (660/818)	8.609	0.003	89.6 (86/96)	91.0 (396/435)	62.0 (178/287)	98.925	<0.001
菌株运输准运证办理流程及文件要求	94.9 (240/253)	88.8 (845/952)	8.298	0.004	97.4 (75/77)	88.8 (316/356)	87.5 (454/519)	6.623	0.037
菌株运输准运证工作满意程度	82.7 (206/249)	75.4 (724/960)	5.959	0.015	79.0 (64/81)	76.9 (279/363)	73.8 (381/516)	1.667	0.435

References 7

[1]	蔡俊丽, 景睿, 张文茜, 等. 2016—2020年济南市肺结核患者耐药情况分析. 结核与肺部疾病杂志, 2022, 3(1): 27-32. doi:10.19983/j.issn.2096-8493.20210138. doi: 10.19983/j.issn.2096-8493.20210138
[2]	冯鑫, 胡彦, 沈静, 等. 2014—2019年重庆市肺结核耐药监测点结核分枝杆菌耐药结果分析. 结核与肺部疾病杂志, 2021, 2(3): 251-255. doi:10.3969/j.issn.2096-8493.20210039. doi: 10.3969/j.issn.2096-8493.20210039
[3]	李勇, 路丽苹, 李瑾, 等. 上海市松江区肺结核患者耐药特征及耐多药结核病影响因素分析. 结核与肺部疾病杂志, 2022, 3(2): 142-147. doi:10.19983/j.issn.2096-8493.20210109. doi: 10.19983/j.issn.2096-8493.20210109
[4]	Jiang GL, Chen X, Song Y, et al. First proficiency testing of second-line anti-tuberculosis drug susceptibility testing in 12 provinces of China. Int J Tuberc Lung Dis, 2013, 17(11): 1491-1494. doi:10.5588/ijtld.13.0275. doi: 10.5588/ijtld.13.0275 pmid: 24125456
[5]	宋媛媛, 赵冰, 夏辉, 等. 2009—2013年全国抗结核药物敏感性试验熟练度测试分析. 中国防痨杂志, 2015, 37(2): 149-156. doi:10.3969/j.issn.1000-6621.2015.02.007. doi: 10.3969/j.issn.1000-6621.2015.02.007
[6]	Ou X, Xia H, Wang S, et al. National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection-China, 2014—2019. China CDC Wkly, 2021, 3(12): 247-251. doi:10.46234/ccdcw2021.072. doi: 10.46234/ccdcw2021.072
[7]	World Health Organization. Practical manual on tuberculosis laboratory strengthening, 2022 update. Geneva: World Health Organization, 2022.

[1]	Senior Department of Tuberculosis, the th Medical Center of Chinese PLA General Hospital, Editorial Board of Chinese Journal of Antituberculosis, Tuberculosis Control Branch of China Intrnational Exchange and Promotive Association for Medical and Health Care. Expert consensus on the diagnosis and treatment of superficial lymph node tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 531-542.
[2]	Senior Department of Tuberculosis, the th Medical Center of Chinese PLA General Hospital, Editorial Board of Chinese Journal of Antituberculosis, Tuberculosis Control Branch of China Intrnational Exchange and Promotive Association for Medical and Health Care. Expert consensus on the clinical application of nucleic acid MALDI-TOF MS technique in the diagnosis of tuberculosis and non-tuberculosis mycobacteriosis [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 543-558.
[3]	He Ping, Wang Yiting, Song Zexuan, Xia Hui, Wang Shengfen, He Wencong, Zheng Yang, Zhao Yanlin. Preliminary study on the gene function of Mycobacterium tuberculosis Rv2333c in macrophages [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 566-574.
[4]	Shang Yaomin, Zhou Xiaolei, Xue Yunling, Leng Xia. Effect of microcard combined with vitamin D on the balance of CD4⁺ T cell subsets in initially treated patients with smear positive pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 575-582.
[5]	Wang Nenhan, Tian Lili, Chen Shuangshuang, Zhao Yanfeng, Fan Ruifang, Chen Hao, Ren Yixuan, Zhang Jie, Yi Junli, Yang Xinyu, Yu Lan, Ding Beichuan, Li Chuanyou, Dai Xiaowei. Study on the detection of rifampicin resistance of Mycobacterium tuberculosis in sputum samples using fluorescence PCR probe melting curve technique [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 583-588.
[6]	Zhang Zhiguo, Shang Yuanyuan, Zhang Xuxia, Liu Rongmei, Ma Liping, Qin Lin, Kong Zhongshun, Ren Weicong. Value of CRISPR-Cas13a detection in the diagnosis of pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 589-593.
[7]	Yang Chao, Wang Jing, Tang Guilin, Geng Yang. Analysis of epidemiological characteristics and treatment outcomes of pulmonary tuberculosis patients in floating population in Tongzhou District of Beijing, 2012—2021 [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 594-600.
[8]	Peng Xiaowang, Fan Xiaolei, Xiang Yang, Maiwulajiang·Yimamu , Hu Pengyuan, Wang Yanjie, Teng Zihao. Analysis of the incidence and risk factors of activepulmonary tuberculosis among close contacts in Kashgar, Xinjiang Uygur Autonomous Region [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 601-606.
[9]	Wang Boning, Li Tao, Chen Wei. Progress on economic burden of patients with drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 607-612.
[10]	Dong Jing, Shi Yuting, Pan Liping, Zhang Zongde. Research progress on long non-coding RNA’s anti infection function against Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 613-619.
[11]	Wen Limin, Hou Dailun. Current status and progress of imaging evaluation methods for detecting pulmonary tuberculosis combined with lung cancer [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 620-624.
[12]	Liao Yixuan, Fang Chuangsen, Li Yanming. Strengthening the capability of non-tuberculosis-designated medical institutions to improve the diagnosis of tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 437-441.
[13]	Wang Dakuan, Zhang Bin, Liu Zisen, Duan Weitao, Gao Lei. Exploration and prospect of the construction of primary tuberculosis preventive treatment clinic [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 442-445.
[14]	Li Shanshan, Wang Yufeng, Shu Wei, Pang Yu. Progress and reflections on development of laboratory diagnostic technology for tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 446-453.
[15]	Shu Wei, Liu Yuhong. Strive for excellence with an emphasis on fundamentals and innovations: interpretation of the WHO Global Tuberculosis Report 2022 [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 454-457.